Fineline Cube

Follow:
14435 Articles
Andon Health to Fully Control iHealth by Acquiring Best Ventures' Stake
CompanyDeals

Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake

Hengrui Pharma's BD Head Dr. Chen Dong Departs for AbbVie's External Innovation Role
Company

Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role

Huadong Medicine's Biosimilar SaiYueXin Seeks NMPA Approval for Crohn's Disease
CompanyDrug

Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease

J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Company

J&J Innovative Medicine China Appoints New General Manager and Oncology VP

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
CompanyDeals

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder

Bayer's Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
CompanyDrug

Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU

Livzon's JP-1366 Injection Gets NMPA Green Light for Peptic Ulcer Bleeding Study
CompanyDrug

Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
CompanyDeals

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform

Lifetech Scientific's Aortic Stent Graft System Wins NMPA Approval
CompanyMedical Device

Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
CompanyDeals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

Eli Lilly Licenses OliX Pharma's OLX75016 for MASH and Cardiometabolic Diseases
CompanyDeals

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Gilead Sciences' Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
Company

Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology